Moderna Rises After Flu Shot Beats Sanofi, GSK Vaccines

CHAM, Switzerland - Nov. 29, 2023 - PRLog -- The business competed against Sanofi's (SNY) Fluzone and GSK's (GSK) Fluarix with its messenger-RNA-based flu vaccine. All three vaccinations are designed to protect against four strains of influenza. According to recent tests, Moderna's vaccine produced more antibodies than already approved vaccinations.

According to Moderna, the experimental flu vaccination accomplished the aim of a final-phase trial. One analyst, however, dubbed the vaccine "a commercial nonstarter," adding that it failed to satisfy the non-inferiority criteria for two influenza strains in a major trial earlier this year. Moderna claims to have improved their recipe since then.

The announcement comes only days after the FDA approved enhanced Covid vaccines from Moderna and Pfizer (PFE) alongside partner BioNTech (BNTX). Meanwhile, the FDA is considering whether to approve Moderna's respiratory syncytial virus vaccine.

Obtaining all three approvals, according to Moderna Chief Financial Officer Jamey Mock, opens the door to a plethora of possible vaccination combinations. Meanwhile, the business is collaborating with Merck (MRK) on a Phase 3 trial of lung cancer patients.

Moderna anticipates launching 15 new items during the next five years. It anticipates an increase in yearly sales of cancer, rare and latent disease medications of $10 billion to $15 billion by 2028, and respiratory treatments of $8 billion to $15 billion in 2027.

Catch up-to-date press release and more at Medical Infralytix Pvt Ltd services, do visit our website at https://meditherma.com/ or contact us thru email.